Loving Richard T, Kripke Daniel F, Elliott Jeffrey A, Knickerbocker Nancy C, Grandner Michael A
Department of Psychiatry, University of California, San Diego, USA.
BMC Psychiatry. 2005 Nov 9;5:41. doi: 10.1186/1471-244X-5-41.
The incidence of insomnia and depression in the elder population is significant. It is hoped that use of light treatment for this group could provide safe, economic, and effective rapid recovery.
In this home-based trial we treated depressed elderly subjects with bright white (8,500 Lux) and dim red (<10 Lux) light for one hour a day at three different times (morning, mid-wake and evening). A placebo response washout was used for the first week. Wake treatment was conducted prior to the initiation of treatment, to explore antidepressant response and the interaction with light treatment. Urine and saliva samples were collected during a 24-hour period both before and after treatment and assayed for aMT6s and melatonin respectively to observe any change in circadian timing. Subjects wore a wrist monitor to record light exposure and wrist activity. Daily log sheets and weekly mood (GDS) and physical symptom (SAFTEE) scales were administered. Each subject was given a SCID interview and each completed a mood questionnaire (SIGH-SAD-SR) before and after treatment. Also, Hamilton Depression Rating (SIGH-SAD version) interviews were conducted by a researcher who was blind to the treatment condition. A control group of healthy, age-matched, volunteers was studied for one day to obtain baseline data for comparison of actigraphy and hormone levels.
Eighty-one volunteers, between 60 and 79 years old, completed the study. Both treatment and placebo groups experienced mood improvement. Average GDS scores improved 5 points, the Hamilton Depression Rating Scale (HDRS) 17 scores (extracted from the self-rated SIGH-SAD-SR) improved 6 points. There were no significant treatment effects or time-by-treatment interactions. No significant adverse reactions were observed in either treatment group. The assays of urine and saliva showed no significant differences between the treatment and placebo groups. The healthy control group was active earlier and slept earlier but received less light than the depressed group at baseline.
Antidepressant response to bright light treatment in this age group was not statistically superior to placebo. Both treatment and placebo groups experienced a clinically significant overall improvement of 16%.
老年人群中失眠和抑郁的发生率较高。希望对该群体使用光照疗法能提供安全、经济且有效的快速康复效果。
在这项居家试验中,我们对老年抑郁受试者分别采用亮白色(8500勒克斯)和暗红色(<10勒克斯)光照,每天一次,每次一小时,在三个不同时间(早晨、睡醒时和晚上)进行治疗。第一周采用安慰剂反应洗脱期。在治疗开始前进行觉醒治疗,以探索抗抑郁反应以及与光照治疗的相互作用。在治疗前后的24小时内收集尿液和唾液样本,分别检测其中的6 - 硫酸褪黑素(aMT6s)和褪黑素,以观察昼夜节律的任何变化。受试者佩戴腕部监测器记录光照暴露和腕部活动情况。发放每日日志表以及每周情绪(老年抑郁量表,GDS)和身体症状(SAFTEE)量表。每位受试者在治疗前后均接受结构性临床访谈(SCID)并完成一份情绪问卷(SIGH - SAD - SR)。此外,由对治疗情况不知情的研究人员进行汉密尔顿抑郁评定量表(SIGH - SAD版)访谈。对一组年龄匹配的健康志愿者进行为期一天的研究,以获取用于比较活动记录仪和激素水平的基线数据。
81名年龄在60至79岁之间的志愿者完成了该研究。治疗组和安慰剂组的情绪均有改善。GDS平均得分提高了5分,汉密尔顿抑郁评定量表17项得分(从自评的SIGH - SAD - SR中提取)提高了6分。未观察到显著的治疗效果或治疗与时间的交互作用。两个治疗组均未观察到显著的不良反应。尿液和唾液检测显示治疗组与安慰剂组之间无显著差异。健康对照组在基线时活动更早且入睡更早,但接受的光照比抑郁组少。
该年龄组对强光治疗的抗抑郁反应在统计学上并不优于安慰剂。治疗组和安慰剂组在临床上均有显著的总体改善,改善率为16%。